Mostrar el registro sencillo del ítem

Síndrome hepatorrenal: revisión de la literatura

dc.contributor.authorAmador A.C.
dc.contributor.authorRodríguez L.J.V.
dc.contributor.authorHernández G.
dc.contributor.authorAguilar D.P.S.
dc.contributor.authorCórdoba P.A.B.
dc.contributor.authorMuñoz J.L.R.
dc.contributor.authorCely M.D.R.
dc.contributor.authorAmador N.F.A.
dc.date.accessioned2024-05-02T14:21:38Z
dc.date.available2024-05-02T14:21:38Z
dc.date.issued2022
dc.identifier.citationAmador, A.C., Rodríguez, L.J.V., Hernández, G., Aguilar, D.P.S., Córdoba, P.A.B., Muñoz, J.L.R., Cely, M.D.R., Amador, N.F.A. Hepatorenal syndrome: Literature review [Article@Síndrome hepatorrenal: revisión de la literatura] (2022) Revista Colombiana de Nefrologia, 9 (1), art. no. e539es_CO
dc.identifier.issn23897708
dc.identifier.otherhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85128332109&doi=10.22265%2facnef.9.1.539&partnerID=40&md5=9709c8137c935092b2cfe942788f7ce1
dc.identifier.urihttp://hdl.handle.net/10818/59965
dc.description9 páginases_CO
dc.description.abstractBackground: Hepatorenal syndrome is a renal dysfunction that occurs in patients with chronic liver disease such as liver cirrhosis or acute liver disease, characterized by the activation of regulatory mechanisms that lead to a decrease in the glomerular filtration rate. Clinically, hepatorenal syndrome is divided into two types, type 1 and type 2. Type 1 is characterized by a rapid and progressive loss of kidney function while type 2 is characterized by slow progression and a better prognosis. Purpose: To analyze the natural history of the disease presented by patients who develop hepatorenal syndrome. Methodology: A review of the scientific literature of published manuscripts on hepatorenal syndrome was carried out to evaluate the natural history of this pathology. Results: There are no specific clinical findings, however, its clinical manifestations reflect the underlying advanced liver disease, kidney failure, and circulatory abnormalities present. Conclusions: The most appropriate therapeutic option is liver transplantation, but not all patients can receive it, while accessing said management an option is drug treatment with vasoconstrictors and albumin. © 2022, Asociacion Colombiana de Nefrologia e Hipertension Arterial. All rights reserved.en
dc.formatapplication/pdfes_CO
dc.publisherRevista Colombiana de Nefrologiaes_CO
dc.relation.ispartofseriesRevista Colombiana de Nefrologia 9 (1), art. no. e539
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad de La Sabanaes_CO
dc.sourceIntellectum Repositorio Universidad de La Sabanaes_CO
dc.subject.otherDiagnosisen
dc.subject.otherHepatorenal syndromeen
dc.subject.otherLiver cirrhorisen
dc.subject.otherRenal failureen
dc.titleHepatorenal syndrome: Literature reviewen
dc.titleSíndrome hepatorrenal: revisión de la literaturaes_CO
dc.typejournal articlees_CO
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsopenAccesses_CO
dc.identifier.doi10.22265/acnef.9.1.539


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International